| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 03/20/2008 | WO2008031322A1 Application of acetylcholine esterase inhibitor medication of leonurus extractive as cholinomimetic |
| 03/20/2008 | WO2008031221A1 Isovaline for treatment of pain |
| 03/20/2008 | WO2008031212A1 Creatine pyroglutamic acid salts and methods for their production and use in individuals |
| 03/20/2008 | WO2008019276A3 Solid forms of (3'-chlorobiphenyl-4-yl)(1-(pyrimidin-2-yl)piperidin-4-yl)methanone and methods of their use |
| 03/20/2008 | WO2008019090A3 Agonists of the sphingosine-1-phosphate receptor |
| 03/20/2008 | WO2008017000A3 Methods and pharmaceutical preparations for contributing to the treatment of chemotherapy-induced neuropathy |
| 03/20/2008 | WO2008016677A3 Preparation and utility of deuterated amphetamines |
| 03/20/2008 | WO2008016661A3 Morpholino compounds for treating inflammatory and demyelinating diseases and cancers |
| 03/20/2008 | WO2008015403A9 Induction of analgesia in neuropathic pain |
| 03/20/2008 | WO2008014247A3 4 -arylalkoxymethyl-4- phenyl piperidines and their use as neurokinin receptor antagonists for the treatment of cns disorders |
| 03/20/2008 | WO2008010223A3 Conjugates comprising a psychotropic drug or a gaba agonist and an organic acid and their use in treating pain and other cns disorders |
| 03/20/2008 | WO2008009866A3 Combination of modafinil and an antagonist or inverse agonist of the h3 receptor |
| 03/20/2008 | WO2008009750A3 Macrocyclic compounds useful as bace inhibitors |
| 03/20/2008 | WO2008004698A3 Pyrazolo [1, 5-a] pyrimidine compounds as cb1 receptor antagonist |
| 03/20/2008 | WO2008003667A3 Combinations of monoamine reuptake inhibitors and potassium channel activators |
| 03/20/2008 | WO2007140358A3 Treatment of polyglutamine-expansion neurodegenerative diseases |
| 03/20/2008 | WO2007133983A3 2-aminobenzimidazoles for treating neurodegenerative diseases |
| 03/20/2008 | WO2007129221A3 Compositions comprising an epi-inositol compounds and methods for treatment of disorders of protein aggregation |
| 03/20/2008 | WO2007113784A3 Methods for modulating the levels and effects of thyrotropin-releasing hormone (trh) and trh-related petides |
| 03/20/2008 | WO2007106617A3 Method of treatment and prophylaxis of diseases related to amyloid deposition using igm |
| 03/20/2008 | WO2007092861A3 Inhibitors specific of presenilin-1 and their uses |
| 03/20/2008 | WO2007072092A8 New phenanthridine derivatives as bradykinin antagonists |
| 03/20/2008 | WO2007054303A3 Diaryl urea for treating diabetic neuropathy |
| 03/20/2008 | WO2007022734A8 A composition for alleviating a hangover comprising hyaluronic acid and activated carbon |
| 03/20/2008 | US20080071233 Pharmaceutical compositions |
| 03/20/2008 | US20080071066 Heparin binding protein for use in controlling angiogenesis and as wound healing agent |
| 03/20/2008 | US20080071065 Fibroblast Growth Factor-Like Polypeptides |
| 03/20/2008 | US20080070995 Methods and Compositions Relating to Alzheimer's Disease |
| 03/20/2008 | US20080070984 antipsychotic drug mixture contains the active drug, also including a colonically absorbable form of levodopa for treating a negative or cognitive symptom in the patient; Levodopa prodrug increase bioavailability, sustained release |
| 03/20/2008 | US20080070974 4-((1E)-2-(((E)-2-fluoro-4-cyanostyrylsulfonyl)methylsulfonyl)vinyl)-3-fluoro-benzonitrile; mitogen activated protein kinase inhibitor; cell growth factor receptor antagonist; angiogenesis inhibitor, antiproliferative and anticarcinogenic agent; neurodegenerative diseases |
| 03/20/2008 | US20080070973 succinate and naphthalenedisulfonate salts and solvates of 2-(Methyloxy)-N-[2-methyl-1-phenyl-2-(1-pyrrolidinyl)propyl]-4,6-bis(trifluoromethyl)benzamide; crystalline; block the glycine site of the NMDA receptors; schizophrenia, dementia, attention deficit disorder; ease of isolation in large scale |
| 03/20/2008 | US20080070964 Opioid receptor active compounds |
| 03/20/2008 | US20080070963 Compositions and methods for promoting neural regeneration |
| 03/20/2008 | US20080070961 storage stability; precipitation |
| 03/20/2008 | US20080070956 ATPase inhibitors; Substituted fluorene or benzenerings joined to an alkylene through a sulfone or sulfoxide linkage; without excessive toxicity, irritation, allergic response etc.; sleep dioredrs like excessive sleepiness; Parkinson's disease; Alzheimer's disease; ADD; ADHA; depression, fatigue |
| 03/20/2008 | US20080070954 inhibitors of histone deacetylase; antiproliferative; anticancer; 8-[3-(4-methylbenzenesulfonyl)-ureido])-octanoic acid hydroxyamide |
| 03/20/2008 | US20080070952 induced by L-dopa or dopamine agonist when treating Parkinson's Disease; administering a selective inhibitor of neuronal Nitric oxide synthase |
| 03/20/2008 | US20080070949 Polymorphs of rimonabant |
| 03/20/2008 | US20080070948 Including indanones, indolinones and benzoxazolinones containing a piperidine ring, e.g., 1-[3-(4-(Hydroxymethyl)piperidin-1-yl)propyl]-1,3-dihydrobenzoimidazol-2-one; particularly for the M1 and/or M4 receptor subtypes; increase acetylcholine signaling or effect in the brain |
| 03/20/2008 | US20080070947 Substituted thiophenes: compositions, processes of making, and uses in disease treatment and diagnosis |
| 03/20/2008 | US20080070946 Hydroxymethylbenzothiazoles Amides |
| 03/20/2008 | US20080070945 4-(2-methyl-5,6,7,8-tetrahydro-quinolin-7-ylmethyl)-1,3-dihydro-imidazole-2-thione as specific alpha2b agonist and methods of using the same |
| 03/20/2008 | US20080070943 Sulfonyldihydroimidazopyridinone compounds as 5-hydroxytryptamine-6 ligands |
| 03/20/2008 | US20080070941 Derivatives of n-heterocyclylmethylbenzamides, preparation method thereof and application of same in therapeutics |
| 03/20/2008 | US20080070940 Side effect reduction of emesis; phosphodiesterase 4 (PDE4) inhibitor; 2-(3'-[3-[(cyclopropylamino)carbonyl)-4-oxo-1,8-naphthyridin-1(4H)-yl]-3-fluoro-1,1'-biphenyl-4-yl)cyclopropanecarboxylic acid, sodium salt; crystalline forms; allergies, autoimmune diseases, cancer, neurodegenerative disorders |
| 03/20/2008 | US20080070937 Small molecule inhibitors of kynurenine-3-monooxygenase |
| 03/20/2008 | US20080070936 Compounds specific to adenosine A1 receptors and uses thereof |
| 03/20/2008 | US20080070935 Isoquinoline, Quinazoline and Phthalazine Derivatives |
| 03/20/2008 | US20080070932 unexpectedly potent antagonists of A2a adenosine receptor; Parkinson's; neurodegenerative diseases; 2-furan-2-yl-N5-[1-(5-methyl-isoxazol-3-ylmethyl)-pyrrolidin-2-ylmethyl]-[1,2,4]triazolo[1,5-a]pyrimidine-5,7-diamine |
| 03/20/2008 | US20080070929 Thiazoline and oxazoline derivatives and their methods of use |
| 03/20/2008 | US20080070928 Novel 2-Heteroaryl-Substituted Benzimidazole Derivative |
| 03/20/2008 | US20080070924 Neurokinin (NK1, substance P) antagonists; used for side effect reduction of emesis, respiratory depression, and opioid tolerance of opioid analgesics; 4-[1-[3,5-bis(trifluoromethyl)benzoyl]-2(phenylmethyl)-4-piperidinyl]-N-(2,6-dimethylphenyl)-1-piperazine acetamide for example |
| 03/20/2008 | US20080070918 Heat Shock Protein-90 (HSP-90) inhibitors; cancer, inflammation, arthritis, angiogenesis, antimalaria, fungal and viral infections; 2-(4-Hydroxy-cyclohexylamino)-4-(3,7,7-trimethyl-5-oxo-5,6,7,8-tetrahydro-4H-cinnolin-1-yl)-benzamide for example; synthesis from corresponding benzonitriles |
| 03/20/2008 | US20080070915 Poly(ADP-ribose)polymerase (PARP); ischemia, reperfusion injuries, neurological disorders, neuroprotectants, sensitizer for chemotherapy or radiotherapy, anticancer |
| 03/20/2008 | US20080070912 Phosphodiesterase inhibitors; neuropathic pain, inflammation, opioid dependence or withdrawal; 2-amino-1-(2-isopropylpyrazolo[1,5-a]pyridin-3-yl)propan-1-one for example |
| 03/20/2008 | US20080070911 Ion channel modulating compounds and uses thereof |
| 03/20/2008 | US20080070905 An enzyme in the tryptophan degradation pathway, used to treat neurodegenerative disorders, certain cancers, drug addiction; 2-sulfonamido-substituted oxazole, imidazole or thiazole compounds such as 3,4-dimethoxy-N-[4-(3-nitrophenyl)-5-dimethylaminomethyl-1,3-thiazole-2-yl]benzenesulfonamide |
| 03/20/2008 | US20080070904 intranasal delivery of lorazepam or diazepam in binary solvents, soluble in 1st solvent ( diethylene glycol, monoethyl ether, tetrahydrofurfuryl alcohol polyethylene glycol), capable of penetrating nasal mucuosa, lesssoluble in 2nd solvent ( propylene glycol, glycerol triacetate); greater bioavailabiltiy |
| 03/20/2008 | US20080070903 New pyrimidine derivatives and new pyridine derivatives |
| 03/20/2008 | US20080070902 Cinnamide Compound |
| 03/20/2008 | US20080070899 (Calcitonin gene related peptide); headache, migraine and cluster headache; spiropiperidine-substituted azepan-2-ones such as 1-(2,2,2-trifluoroethyl)-3-(1-oxo-2,8-diazaspiro[4.5]decan-8-yl-aminocarbonylamino)6-(2,3-difluorophenyl)azepan-2-one |
| 03/20/2008 | US20080070898 Sodium channel inhibitor of low side effect; analgesics; neuropathic pain; 4-(2-{4-[(E)-2-(2-methylphenyl)vinyl]piperidin-1-yl}-2-oxoethyl)morpholine for example |
| 03/20/2008 | US20080070897 Having high bioavailability levels and reduced variability of bioavailability by use of dispersed, colloidal structures, colloids or analogous structures of the drug, a hydrophilic component (ethanol) , a surfactant such as polyglycerol, polyoxyethylene castor oil |
| 03/20/2008 | US20080070895 Heteroaryl substituted spirocyclic sulfamides for inhibition of gamma secretase |
| 03/20/2008 | US20080070893 Cancer, neurological disorders, autoimmune disorders; inhibitors of CK2, a serine/threonine kinase; based upon macrocyclic pyrazolo[1,5-a][1,3,5]triazine and pyrazolo[1,5-a]pyrimidine compounds |
| 03/20/2008 | US20080070891 (1s,5s)-3-(5,6-dichloro-3-pyridinyl)-3,6-diazabicyclo[3.2.0]heptane |
| 03/20/2008 | US20080070888 Spirocyclic azetidin(one); 2-(3-chloro-4-fluorophenyl)-7-[5-fluoro-6-(trifluoromethyl)-1H-benzimidazol-2-yl]-3-(2-pyridinyl)-2,7-diazaspiro[3.5]nonan-1-one; T-type calcium channel blockers |
| 03/20/2008 | US20080070885 disorders related to beta-amyloid such as Alzheimer's disease, Down's Syndrome, memory and cognitive impairment, dementia, amyloidosis; (2R,4S) N-Butyl-4-hydroxy-2-methyl-4-((10S,13S)-10-methyl-8,11-dioxo-2-oxa-9,12-diaza-bicyclo[13.3.1]nonadeca-1(18),15(19),16-trien-13-yl)-butyramide for example |
| 03/20/2008 | US20080070876 Gaba-Steroid Antagonists And Their Use For The Treatment Of Cns Disorders |
| 03/20/2008 | US20080070870 Using 3-omega fatty acid rich marine phospholipid, made by reacting soybean or egg lecithin with docosahexanoic acid and eicosapentaenoic acid in presence of lipase enzyme, for memory loss, forgetfulness, short-term memory loss, aphasia, disorientation, disinhibition, and behavioral changes |
| 03/20/2008 | US20080070864 Modulating the activity of farnesoid X receptor (FXR) and/or orphan nuclear receptors; N-[3-(2,4-dimethylphenyl)-4-oxo-3,4-dihydroquinazolin-2-ylmethyl]benzenesulfonamide |
| 03/20/2008 | US20080070843 Protein kinase inhibitors comprising atp mimetics conjugated to peptides or peptidomimetics |
| 03/20/2008 | US20080070833 Lactoferrin in the reduction of pain |
| 03/20/2008 | US20080070267 changing the pattern of Ca2+ spike activity of the neuron; treating psychological disorder using electrical or chemical stimulants, or antagonist; altering neurotransmitter expression; autism, anxiety disorder, post-traumatic stress disorder, depression, bipolar disorder and schizophrenia |
| 03/20/2008 | US20080070259 Using presence or absence of mutation in metalloenzyme polynucleotides as diagnostic indicator of cardiovascular and neurodegenerative disorders |
| 03/20/2008 | US20080069903 Electrical producing creams |
| 03/20/2008 | US20080069891 Abuse resistant drug formulation |
| 03/20/2008 | US20080069885 Sustained release microparticle; a biodegradable and biocompatible polymer; active agent risperidone, 9-hydroxy-risperidone; pharmaceutically acceptable acid addition salts; inhibiting serotonergic or dopaminergic overstimulation |
| 03/20/2008 | US20080069881 Abuse-resistant controlled-release opioid dosage form |
| 03/20/2008 | US20080069873 Controlled release system and method for manufacturing the same |
| 03/20/2008 | US20080069872 Maintenance of therapeutic concentration in blood; core with protective coating |
| 03/20/2008 | US20080069871 Hydrophobic abuse deterrent delivery system |
| 03/20/2008 | US20080069848 Device, method, and use for treatment of neuropathy involving nitric oxide |
| 03/20/2008 | US20080069841 Pharmaceutical Compositions Containing Botulinum Neurotoxin A2 |
| 03/20/2008 | US20080069773 Novel Sodium Channel |
| 03/20/2008 | DE102006030479A1 Indazolderivate Indazole derivatives |
| 03/20/2008 | DE10080167B4 Medikament zur Hemmung der Expression eines vorgegebenen Gens Medicament for inhibiting the expression of a given gene |
| 03/20/2008 | CA2664251A1 Isovaline for treatment of pain |
| 03/20/2008 | CA2663504A1 Azetidine and azetidone derivatives useful in treating pain and disorders of lipid metabolism |
| 03/20/2008 | CA2663503A1 Azetidinone derivatives and methods of use thereof |
| 03/20/2008 | CA2663501A1 Treating pain, diabetes, and disorders of lipid metabolism |
| 03/20/2008 | CA2663234A1 Novel phenylacetic acid derivative |
| 03/20/2008 | CA2663161A1 Quinazolinone and isoquinolinone acetamide derivatives |
| 03/20/2008 | CA2662937A1 Multi-functional small molecules as anti-proliferative agents |
| 03/20/2008 | CA2662538A1 Azabicyclic compounds as inhibitors of monoamines reuptake |
| 03/20/2008 | CA2662409A1 5-phenyl-nicotinamide derivatives |
| 03/20/2008 | CA2662115A1 Methods for enhancing cognitive function |
| 03/19/2008 | EP1900815A2 In vivo production of small interfering RNAs that mediate gene silencing |
| 03/19/2008 | EP1900811A1 Enriched central nervous system cell populations |
| 03/19/2008 | EP1900738A2 Substituted pyrroline kinase inhibitors |